| Date | Title | Description |
| 18.04.2024 | PainReform Announces Closing of $4 Million Public Offering | - |
| 17.04.2024 | TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering | WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment... |
| 17.04.2024 | TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering | - |
| 16.04.2024 | Silver Mountain Announces $7.5 Million Public Offering | - |
| 16.04.2024 | TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering | - |
| 12.04.2024 | Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering | SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 pe... |
| 11.04.2024 | Longeveron Announces Closing of $5.2 Million Public Offering | MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as... |
| 11.04.2024 | Longeveron Announces Closing of $5.2 Million Public Offering | - |
| 11.04.2024 | Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering | - |
| 08.04.2024 | i-80 Announces C$86 Million Bought Deal Public Offering of Units | - |
| 08.04.2024 | i-80 Announces C$86 Million Bought Deal Public Offering of Units | /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES/
RENO, Nev., April 08, 2024 (GLOBE NEWSWIRE) -- i-80 Gold Corp. (TSX:IAU) (NYSE:IAUX) (“i-80” or the “Company”) is pleased to announce that i... |
| 01.04.2024 | Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering | - |
| 28.03.2024 | Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering | - |
| 21.03.2024 | ReconAfrica Announces C$10 Million Bought-Deal Public Offering | - |
| 19.03.2024 | C3is Inc. Announces Closing of $6.0 Million Underwritten Public Offering | - |
| 18.03.2024 | Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering | - |
| 15.03.2024 | C3is Inc. Announces Pricing of $6.0 Million Underwritten Public Offering | - |
| 07.03.2024 | Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering | - |
| 05.03.2024 | Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering | - |
| 01.03.2024 | Tarsus Announces Pricing of $100.0 Million Public Offering | IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for ... |
| 01.03.2024 | Tarsus Announces Pricing of $100.0 Million Public Offering | - |
| 29.02.2024 | Tarsus Announces Proposed $100.0 Million Public Offering | IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for p... |
| 29.02.2024 | Arcutis Announces Pricing of $150 Million Public Offering | WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pr... |
| 29.02.2024 | Tarsus Announces Proposed $100.0 Million Public Offering | - |
| 28.02.2024 | Arcutis Announces Pricing of $150 Million Public Offering | - |
| 28.02.2024 | Agrify Corporation Announces Pricing of $2.6 Million Public Offering | - |
| 27.02.2024 | Aclarion Announces Closing of $3.0 Million Public Offering | - |
| 26.02.2024 | Aclarion Announces Pricing of $3.0 Million Public Offering | - |
| 26.02.2024 | Draganfly Announces Closing of US$3.6 Million Underwritten Public Offering | Saskatoon, SK., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), a drone solutions, and systems developer, today announced the closing of its previously announced underw... |
| 26.02.2024 | Draganfly Announces Closing of US$3.6 Million Underwritten Public Offering | - |
| 22.02.2024 | Colliers International Group Inc. Announces US$300 Million Bought Deal Public Offering of Equity | TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers” or the “Company”) has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital ... |
| 22.02.2024 | Colliers International Group Inc. Announces US$300 Million Bought Deal Public Offering of Equity | - |
| 21.02.2024 | Draganfly Announces Pricing of US$3.6 Million Underwritten Public Offering | - |
| 16.02.2024 | ToughBuilt Industries Announces Closing of $3.5 Million Public Offering | - |
| 14.02.2024 | ToughBuilt Industries Announces Pricing of $3.5 Million Public Offering | - |
| 14.02.2024 | Evoke Pharma Announces Closing of $7.5 Million Public Offering | - |
| 12.02.2024 | Beamr Imaging Ltd. Announces Pricing of $12 Million Public Offering | - |
| 08.02.2024 | Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering | CHAPEL HILL, N.C., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary disea... |
| 08.02.2024 | Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering | - |
| 07.02.2024 | Phunware Announces Pricing of $10.0 Million Public Offering | - |
| 06.02.2024 | Cingulate Announces Closing of $7.5 Million Public Offering | - |
| 06.02.2024 | Evaxion Announces Closing of $15 Million Public Offering | - |
| 05.02.2024 | BullFrog AI Announces Closing of $5.7 Million Public Offering | - |
| 02.02.2024 | SINTX Technologies Announces Closing of $4.0 Million Public Offering | - |
| 02.02.2024 | Cingulate Announces Pricing of $7.5 Million Public Offering | - |
| 02.02.2024 | SINTX Technologies Announces Closing of $4.0 Million Public Offering | SALT LAKE CITY, UT, Feb. 02, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced the closing of its previously announced publi... |
| 02.02.2024 | GRI Bio Announces Pricing of $5.5 Million Public Offering | LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory... |
| 02.02.2024 | Cingulate Announces Pricing of $7.5 Million Public Offering | KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platfo... |
| 02.02.2024 | GRI Bio Announces Pricing of $5.5 Million Public Offering | - |
| 01.02.2024 | Panbela Announces Closing of Approximately $9.0 Million Public Offering | - |
| 01.02.2024 | Bullfrog AI Announces Pricing of $5.7 Million Public Offering | - |
| 01.02.2024 | Evaxion Biotech Announces Pricing of $15 Million Public Offering | - |
| 01.02.2024 | Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering | HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to impro... |
| 01.02.2024 | Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering | - |
| 31.01.2024 | SINTX Technologies Announces Pricing of $4.0 Million Public Offering | - |
| 31.01.2024 | 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering | - |
| 30.01.2024 | Vaxcyte Announces Pricing of $750 Million Public Offering | - |
| 30.01.2024 | 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering | - |
| 29.01.2024 | Panbela Announces Pricing of Approximately $9.0 Million Public Offering | - |
| 26.01.2024 | Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering | - |
| 26.01.2024 | Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering | HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to impr... |
| 23.01.2024 | C3is Inc. Announces Closing of $7.0 Million Upsized Underwritten Public Offering | - |
| 23.01.2024 | C3is Inc. Announces Closing of $7.0 Million Upsized Underwritten Public Offering | Athens, GREECE, Jan. 23, 2024 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing dry bulk and crude oil tanker seaborne transportation services, today announced the closing of a firm commitment und... |
| 22.01.2024 | TransCode Therapeutics Announces Closing of $7.25 Million Public Offering | - |
| 22.01.2024 | SurgePays Announces Closing of $15 Million Public Offering | - |
| 19.01.2024 | C3is Inc. Announces Pricing of $7.0 Million Upsized Underwritten Public Offering | ATHENS, Greece, Jan. 19, 2024 (GLOBE NEWSWIRE) -- C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing dry bulk and crude oil tanker seaborne transportation services, today announced the pricing of a firm commitment und... |
| 19.01.2024 | C3is Inc. Announces Pricing of $7.0 Million Upsized Underwritten Public Offering | - |
| 18.01.2024 | TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering | - |
| 18.01.2024 | VCI Global Announces Closing of $2.75 Million Public Offering | - |
| 17.01.2024 | Immatics Announces Pricing of $175 Million Public Offering | - |
| 17.01.2024 | Genius Group Announces Closing of $8.25 Million Public Offering | - |
| 17.01.2024 | SurgePays Announces Pricing of $15 Million Public Offering | - |
| 15.01.2024 | XORTX Announces $2 Million Public Offering | - |
| 15.01.2024 | XORTX Announces $2 Million Public Offering | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES
CALGARY, Alberta, Jan. 15, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt... |
| 12.01.2024 | VCI Global Announces Pricing of $2.75 Million Public Offering | KUALA LUMPUR, Malaysia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) today announced the pricing of a public offering of 2,200,000 the Company’s ordinary shares and accompanying Series... |
| 12.01.2024 | Genius Group Announces Pricing of $8.25 Million Public Offering | SINGAPORE, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading entrepreneur edtech and education group, today announced the pricing of a public offering of 23,571,429 of t... |
| 12.01.2024 | Genius Group Announces Pricing of $8.25 Million Public Offering | - |
| 11.01.2024 | Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering | - |
| 11.01.2024 | VCI Global Announces Pricing of $2.75 Million Public Offering | - |
| 09.01.2024 | Roma Green Finance Limited Announces Pricing of $12,300,000 Public Offering | - |
| 05.01.2024 | Kymera Therapeutics Announces Pricing of $275 Million Public Offering | WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today annou... |
| 05.01.2024 | Kymera Therapeutics Announces Pricing of $275 Million Public Offering | - |
| 04.01.2024 | SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering | - |
| 02.01.2024 | Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering | - |
| 28.12.2023 | Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering | - |
| 19.12.2023 | Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering | - |
| 18.12.2023 | Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering | - |
| 15.12.2023 | Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering | - |
| 14.12.2023 | Eos Energy Announces Launch of Proposed $40M Public Offering | - |
| 11.12.2023 | Red Cat Holdings, Inc. Announces Closing of $9.2 Million Public Offering | - |
| 11.12.2023 | Phunware Announces Closing of $2.8 Million Public Offering | - |
| 07.12.2023 | ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering | WESTON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or “the Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and... |
| 06.12.2023 | ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering | - |
| 05.12.2023 | iBio, Inc. Announces Pricing of $4.5 Million Public Offering | - |
| 05.12.2023 | HEALWELL AI Announces $8 Million Bought Deal Public Offering | - |
| 30.11.2023 | Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering | VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,4... |
| 30.11.2023 | Treasure Global Inc Announces Closing of $4.0 Million Public Offering | - |
| 30.11.2023 | Treasure Global Inc Announces Closing of $4.0 Million Public Offering | NEW YORK and KUALA LUMPUR, Malaysia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Treasure Global Inc (NASDAQ: TGL) (“TGL” or the “Company”) today closed its previously announced underwritten public offering of 26,014,000 shares (the “Shares”) of comm... |
| 29.11.2023 | Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering | - |
| 29.11.2023 | Treasure Global Inc Announces Pricing of $4.0 Million Underwritten Public Offering | - |